J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Escolà-Gil, J. C.
Right arrow Articles by Blanco-Vaca, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Escolà-Gil, J. C.
Right arrow Articles by Blanco-Vaca, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 42, 241-248, February 2001
Copyright © 2001 by Lipid Research, Inc.


Original Article

ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance

Joan Carles Escolà-Gila,b, Josep Julvea,b, Àfrica Marzal-Casacubertaa,b, Jordi Ordóñez-Llanosa,c, Francesc González-Sastrea,c, and Francisco Blanco-Vacaa,b
a Servei de Bioquímica, de l'Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
b Institut de Recerca, de l'Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
c Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain

Correspondence to: Francisco Blanco-Vaca, at Hospital de la Santa Creu i Sant Pau, Servei de Bioquímica, C/ Antoni M. Claret, 167, 08025 Barcelona, Spain., fblanco{at}santpau.es (E-mail)

Apolipoprotein (apo)A-II is a major high density lipoprotein (HDL) protein; however, its role in lipoprotein metabolism is largely unknown. Transgenic (Tg) mice that overexpress human apoA-II present functional lecithin: cholesterol acyltransferase deficiency, HDL deficiency, hypertriglyceridemia and, when fed an atherogenic diet, increased non-HDL cholesterol and increased susceptibility to atherosclerosis. In contrast to humans, mice do not present cholesteryl ester transfer protein (CETP) activity in plasma. To study the in vivo interaction of these two proteins, we crossbred human apoA-II and CETP-Tg mice. CETPxapoA-II-Tg mice fed an atherogenic diet, compared with CETP-Tg mice presented a 2-fold decrease in HDL cholesterol and a quantitatively similar increase in total plasma cholesterol and percentage of free cholesterol, non-HDL cholesterol, and free fatty acids, together with a remarkable 112-fold increase in plasma triglycerides. Plasma triglycerides in CETPxapoA-II-Tg mice were mainly associated with very low density lipoproteins (VLDL), which were also enriched in protein content, and resulted from a combination of higher production rate compared with both of their progenitors and non-Tg control mice, and decreased catabolism compared only with CETP-Tg mice.

These results show CETPxapoA-II-Tg mice to be a good model with which to study mechanisms leading to VLDL overproduction and suggest that CETP and, in particular apoA-II, may play a role in the regulation of VLDL metabolism. Escolà-Gil, J. C., J. Julve, À. Marzal-Casacuberta, J. Ordóñez-Llanos, F. González-Sastre, and F. Blanco-Vaca. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J. Lipid Res. 2001. 42: 241;–248.

Supplementary key words: atherosclerosis, cholesteryl ester transfer protein, high density lipoprotein, hypertrygliceridemia, very low density lipoprotein, familial combined hyperlipidemia


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. W. Castellani, C. N. Nguyen, S. Charugundla, M. M. Weinstein, C. X. Doan, W. S. Blaner, N. Wongsiriroj, and A. J. Lusis
Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance
J. Biol. Chem., April 25, 2008; 283(17): 11633 - 11644.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
J. Delgado-Lista, F. Perez-Jimenez, T. Tanaka, P. Perez-Martinez, Y. Jimenez-Gomez, C. Marin, J. Ruano, L. Parnell, J. M. Ordovas, and J. Lopez-Miranda
An Apolipoprotein A-II Polymorphism (-265T/C, rs5082) Regulates Postprandial Response to a Saturated Fat Overload in Healthy Men
J. Nutr., September 1, 2007; 137(9): 2024 - 2028.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Rotllan, V. Ribas, L. Calpe-Berdiel, J. M. Martin-Campos, F. Blanco-Vaca, and J. C. Escola-Gil
Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo
Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): e128 - e132.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. W. Castellani, P. Gargalovic, M. Febbraio, S. Charugundla, M.-L. Jien, and A. J. Lusis
Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II
J. Lipid Res., December 1, 2004; 45(12): 2377 - 2387.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
V. Ribas, J. L. Sanchez-Quesada, R. Anton, M. Camacho, J. Julve, J. C. Escola-Gil, L. Vila, J. Ordonez-Llanos, and F. Blanco-Vaca
Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties: A New Mechanism Linking HDL Protein Composition and Antiatherogenic Potential
Circ. Res., October 15, 2004; 95(8): 789 - 797.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. C. de Beer, L. W. Castellani, L. Cai, A. J. Stromberg, F. C. de Beer, and D. R. van der Westhuyzen
ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36
J. Lipid Res., April 1, 2004; 45(4): 706 - 715.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. Julve, J. C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J. L. Sanchez-Quesada, and F. Blanco-Vaca
Mechanisms of HDL deficiency in mice overexpressing human apoA-II
J. Lipid Res., October 1, 2002; 43(10): 1734 - 1742.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Luc, J.-M. Bard, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.-C. Fruchart, P. Ducimetiere, and on behalf of the PRIME Study Group
Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study
Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1155 - 1161.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
F. Blanco-Vaca, J. C. Escola-Gil, J. M. Martin-Campos, and J. Julve
Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein
J. Lipid Res., November 1, 2001; 42(11): 1727 - 1739.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. M. van 't Hooft, G. Ruotolo, S. Boquist, U. de Faire, G. Eggertsen, and A. Hamsten
Human Evidence That the Apolipoprotein A-II Gene Is Implicated in Visceral Fat Accumulation and Metabolism of Triglyceride-Rich Lipoproteins
Circulation, September 11, 2001; 104(11): 1223 - 1228.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.